Abstract：Objective To observe the expression of serum matrix metalloproteinase-2（MMP-2）and interleukin-6（IL-6）in patients with advanced gastric cancer（AGC）,and to analyze their effects on the prognosis of neoadjuvant chemotherapy.Methods A total of 70 patients with AGC were selected,and all patients received 3 courses of neoadjuvant chemotherapy.The effect of 3 courses of treatment was observed and recorded as a short-term prognosis indicator,and the patients were divided into a poor prognosis group and a good prognosis group.The baseline data and serum MMP-2 and IL-6 levels of both groups were investigated and compared,and the effects of serum MMP-2 and IL-6 levels on the prognosis of neoadjuvant chemotherapy were analyzed.Results After 3 courses of chemotherapy,33 of the 70 patients had poor prognosis,accounting for 47.14%.Compared with the good prognosis group,the serum MMP-2 and IL-6 levels were higher of patients in the poor prognosis group（P<0.05）.Logistic regression analysis showed that the overexpression of serum MMP-2 and IL-6 at admission was an influencing factor for the poor prognosis of AGC patients with neoadjuvant chemotherapy（OR>1,P<0.05）.Conclusion The overexpression of serum MMP-2 and IL-6 suggests that patients with AGC have a higher risk of poor prognosis after neoadjuvant chemotherapy.
赵永春, 刘锦云, 刘晓瑞. 血清MMP-2、IL-6水平对进展期胃癌患者新辅助化疗预后的影响[J]. 哈尔滨医药, 2023, 43(1): 21-23.
Zhao Yongchun, Liu Jinyun, Liu Xiaorui. Effect of Serum MMP-2 and IL-6 Levels on the Prognosis of Advanced Gastric Cancer Patients With Neoadjuvant Chemotherapy. journal1, 2023, 43(1): 21-23.
2023, Vol. 43 
